Considering that current glaucoma treatments target secondary outflow mechanisms or incur side effects (such as hyperemia) (70, 71), the IOP lowering achieved through TRPV4 inhibition and gene knockdown promises a novel therapeutic avenue to mitigate ocular injury. Here, TRPV4 is linked to glaucoma.